SHA: 603707

Company Drug

Nanjing King-Friend Bio’s Biosimilar Victoza Approved by FDA

Fineline Cube Apr 7, 2025

China-based Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (SHA: 603707) announced that its Abbreviated New Drug...

Company Deals

China’s Kingfriend Biochemical Acquires U.S.-Listed Adalimumab Biosimilar Yusimry for USD 40 Million

Fineline Cube Jun 28, 2024

Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced the...

Company

Nanjing Kingfriend Biochemical Gets FDA Nod for Dacarbazine Manufacture at Sagent Facility

Fineline Cube Jun 3, 2024

Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced that...

Policy / Regulatory

U.S. Tariffs on Pharmaceuticals and Their Impact on China’s Medical Industry

Company Drug

Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma

Company Drug

AbbVie’s Rinvoq Approved in EU for Giant Cell Arteritis

Company Drug

Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved for MSI-H Colorectal Cancer